Attached files
file | filename |
---|---|
EX-99 - ADDITIONAL EXHIBITS - Monopar Therapeutics | mnprnorthstarpressrelease.htm |
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 16,
2020
MONOPAR
THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-39070
|
|
32-0463781
|
(State or other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
1000
Skokie Blvd., Suite 350, Wilmette,
IL 60091
|
|
60091
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
(847)
388-0349
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.001 par value
|
|
MNPR
|
|
The
Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 Regulation FD Disclosure
On June 16, 2020, Monopar Therapeutics Inc.
(“Monopar”) issued a press
release annoucing a development collaboration with NorthStar
Medical Radioisotopes, LLC to research and develop potential
Radio-Immuno-Therapeutics (“RITs”) to treat severe
COVID-19 (patients with SARS-CoV-2).
The
press release is furnished as Exhibit 99.1 to this report and
incorporated herein by reference.
Item 8.01 Other Information
On June
15, 2020, Monopar executed a development collaboration agreement
with NorthStar Medical Radioisotopes, LLC
(“NorthStar”), a privately-held commercial producer and
supplier of medical radioisotopes based in Beloit, Wisconsin to
develop a potential treatment for severe COVID-19.
The
agreement combines NorthStar’s medical radioisotope expertise
with Monopar’s expertise in therapeutic drug development and
its pre-IND stage humanized urokinase plasminogen activator
receptor (“uPAR”) targeted monoclonal antibody known as
MNPR-101, along with a proprietary portfolio of related monoclonal
antibodies that target uPAR or its ligand uPA.
Each
company will start out sharing development costs 50/50, and the
initial financial commitment for each company is nominal.
Additional financial contributions will be subject to mutual
agreement of the parties. Each party will retain all existing
intellectual property rights and will grant the other party a
royalty-free, non-exclusive license to the intellectual property
necessary to perform the development activities contemplated by the
agreement. Intellectual property developed in the course of
performance of the agreement that relates to the targeted product
would be jointly owned.
The
agreement provides an initial framework for design and development
activities. It is expected that the first several months of the
collaboration will focus on identifying the linker and radioisotope
to conjugate to MNPR-101 or other Monopar antibodies. Additional
capital would be required to complete preclinical and clinical
development, and if successful, commercialization. If the research
is successful, the agreement provides that the companies would
negotiate a commercialization plan at that time, including the
ongoing contributions of each company and respective revenue
sharing.
The
agreement has a ten-year term, but either party may terminate the
agreement upon 30 days’ written notice.
Item 9.01 Financial Statements and Exhibits
Exhibit No.
|
Description
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Monopar
Therapeutics Inc.
|
|
|
|
|
|
|
Date: June 16,
2020
|
By:
|
/s/
Kim
R. Tsuchimoto
|
|
|
|
Name: Kim
R. Tsuchimoto
|
|
|
|
Title:
Chief
Financial Officer, Secretary and Treasurer
|
|